Highlighting Latest Additions to the Treatment Landscape for AML
Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.
Alexander E. Perl, MD, associate professor in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania, and member of the Abramson Cancer Center, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia (AML). These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.
Over the last few years, there have been 9 new drug approvals for AML, says Perl, after many years with no drug developments. Many of these newer drugs are targeting the specific biologic processes that are often driven by the mutations seen in AML.
For example, a drug called gilteritinib (Xospata) is a new therapy for patients with AML. This agent targets a very common mutation calledFLT3.These data were presented at the 2019 AACR Meeting
